Perrigo Company Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 9/30/2026)
| Balance Sheet | Total Assets | 8,535,200,000.00 | ROE | 34.39 % |
| Balance Sheet | Total Equity | 2,935,500,000.00 | ROA | -16.70 % |
| Cashflow | Capital Expenditures | -93,400,000.00 | P/FCF | 15.22 |
| Cashflow | Free Cash Flow | 145,100,000.00 | – | – |
| Cashflow | Operating Cash Flow | 238,500,000.00 | P/CF | 9.26 |
| Income | Earnings per Share (diluted) | -10.29 | Div. Yield | 7.27 % |
| Income | Net Income | -1,425,400,000.00 | P/E | -1.55 |
| Income | Shares Outstanding | 138,500,000.00 | P/B | 0.75 |
| Income | Total Revenue | 4,253,100,000.00 | P/S | 0.52 |
Ratios calculated on: 10/14/2026
Company Description
A Leading Global Over-The-Counter Pharmaceutical Company A top five global over-the-counter (OTC) consumer goods and pharmaceutical company, Perrigo Company plc offers customers and consumers high quality products, across a variety of categories, at affordable prices. Perrigo is the world's largest manufacturer of OTC products and supplier of infant formulas for the store brand market. The Company is also a leading provider of branded OTC products, generic extended topical prescription products and receives royalties from Multiple Sclerosis drug Tysabri®. Perrigo's store brand OTC leadership position is derived from years of expertise, which is combined with world class manufacturing technologies and advanced distribution capabilities, allowing us to provide a range of services that is unmatched in our industry.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.perrigo.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more